natgillin/translations-raw huggingface dataset:
The majority of patients were successfully re-challenged with alglucosidase alfa using lower doses and/or pretreatment with anti- inflammatory drugs and/or corticosteroids and have continued to receive treatment under close clinical supervision.
Pri večini bolnikov je bila ponovna uporaba alglukozidaze alfa ob uporabi manjših odmerkov in/ali predhodnem zdravljenju s protivnetnimi zdravili in/ali kortikosteroidi uspešna in so še naprej prejemali alglukozidazo alfa pod skrbnim kliničnim nadzorom.
The majority of patients who lost response and resumed ustekinumab did so within 24 weeks of the induction infusion.
Bolnikom naročite, naj se posvetujejo z zdravnikom, če se pojavijo znaki ali simptomi, ki kažejo na okužbo.
The majority of patients who were positive for antibodies to ustekinumab had neutralizing antibodies.
Večina bolnikov, pri katerih so dokazali protitelesa proti ustekinumabu, je imela nevtralizirajoča protitelesa.
The majority of patients with elevations had hepatic transaminases that were <3 times the upper limit of normal (ULN).
Večina bolnikov z zvišanji je imela jetrne transaminaze, < 3-krat višje od zgornje normalne vrednosti (ULN, upper limit of normal).
The majority of rashes associated with nevirapine occur within the first 6 weeks of initiation of therapy.
Izpuščaj, ki je povezan z nevirapinuom, se večinoma pojavi v prvih 6 tednih po začetku zdravljenja.
The majority of reported TNF-antagonist cases occurred in adolescent and young adult males with Crohn’s disease or ulcerative colitis.
Večina bolnikov, zdravljenih z zaviralci TNF, pri katerih se je pojavil hepatosplenični limfom celic T, so bili mladostniki in mladi, odrasli moški s Crohnovo boleznijo ali ulceroznim kolitisom.
The majority of side effects are mild and transient.
Večina neželenih učinkov je bila blagih in prehodnih.
The majority of side effects are mild or moderate in severity, and the most serious is pneumonia.
Večina neželenih učinkov je blagih do zmernih, najresnejši je pljučnica.
The majority of skin and subcutaneous adverse reactions were associated with the injection site.
Z jetri povezani neželeni učinki
The majority of subjects, 33 (77%), were considered to have ‘primary refractory disease’, defined as having no prior adequate response to IST in any lineage.
Pri večini preiskovancev, to je pri 33 (77 %), so ocenili, da gre za “primarno neodzivno bolezen”, ki je opredeljena s tem, da pri bolniku predhodno še pri nobeni od linij krvnih celic ni prišlo do zadostnega odziva na imunosupresivno zdravljenje.
The majority of the adverse drug reactions (ADRs) reported from trials were gastrointestinal disorders, with the most frequently reported ADRs being diarrhoea and discoloured faeces (very common).
Večina neželenih učinkov, o katerih so poročali v preskušanjih, so bile gastrointestinalne težave, najpogostejši neželeni učinek pa sta bila diareja in sprememba barve blata (zelo pogosta).
The majority of the adverse reactions of increased CPK observed in all double-blind and open-label studies resolved and were considered mild in severity.
Večino neželenih učinkov povečane CPK, ki so jih smatrali za blage. so opazili v vseh dvojno slepih in odprtih študijah.
The majority of the events occurred in cycle 1, all were assessed as treatment-related, and the majority of the reports were Grade 1 or 2.
Večina primerov se je pojavila v 1. ciklu, za vse so ocenili, da so povezani z zdravljenjem in večina poročil je bila 1. ali 2. stopnje.
The majority of the events were mild to moderate.
Neželeni dogodki so bili večinoma blago do zmerno izraženi.
The majority of the excised lesions reviewed by an independent central dermatopathology laboratory were classified as SCC- keratoacanthoma subtype or with mixed-keratoacanthoma features (52%).
Večina izrezanih sprememb, ki jih je pregledal neodvisen centralni histopatološki laboratorij, je bilo opredeljenih kot ploščatocelični karcinom keratoakantomske podvrste ali z mešanimi keratoakantomskimi značilnostmi (52 %).
The majority of the patients had Grade 1 or 2 events (≥ 50,000/mm3), with the nadir occurring by day 8 and generally improving to Grade 0 or 1 (≥ 75,000/mm3) by the next scheduled dose.
Večina bolnikov je imela ta učinek 1. ali 2. stopnje (≥ 50.000/mm3); najnižja vrednost je bila dosežena do 8. dne in se je na splošno izboljšala na stopnjo 0 ali 1. stopnjo (≥ 75.000/mm3) do naslednjega predvidenega odmerka.
The majority of the patients in both groups completed treatment, 80% in the BR-CAP group and 82% in the R-CHOP group.
Večina bolnikov v obeh skupinah je zdravljenje zaključila, 80% v skupini BzR-CAP in 82% v skupini R-CHOP.
The majority of the patients in study GAO4753g had follicular lymphoma (FL) (81.1%).
Večina bolnikov v študiji GAO4753g je imela folikularni limfom (FL) (81,1 %).
The majority of the patients showed sustained reversal of dabigatran plasma concentrations up to 12 hours (>90%).
Pri večini bolnikov je bilo zaznati do 12 ur trajajoče izničenje plazemskih koncentracij dabigatrana (> 90%).
The majority of the SAEs experienced were gastrointestinal disorders (8% - 11 patients), specifically nausea (3% - 4 patients), vomiting (3% - 4 patients) and upper abdominal pain (2% - 2 patients).
Večina HNU so bile prebavne motnje (8% – 11 bolnikov), posebno slabost (3% – 4 bolniki), bruhanje (3% – 4 bolniki) in bolečine v zgornjem delu trebuha (2% – 2 bolnika).
The majority of the side effects, such as fever and chills, pain in the muscles or joints, and headache, occur within the first three days following the dose of Zoledronic acid Teva Generics.
Večina neželenih učinkov, kot so vročina z mrzlico, bolečine v mišicah in sklepih in glavobol, nastopi v prvih treh dneh po odmerku zdravila Zoledronska kislina Teva Generics.
The majority of these events were mild in severity.
Večinoma je šlo za blago izražene primere.
The majority of these rated the importance of this change to be Important to Extremely Important in performing their activities of daily living (79 - 86% at week 2).
Večina teh bolnikov je ocenila spremembo kot pomembno do izredno pomembno za opravljanje vsakodnevnih dejavnosti (79 – 86 % 2. teden).
The majority of these reactions usually disappear within 1-2 days without treatment.
Večina teh reakcij navadno izgine v 1 do 2 dneh brez zdravljenja.
The majority of these reactions were maculopapular or urticarial rashes.
Večina teh reakcij je bila makulopapuloznih ali urtikarialnih izpuščajev.
The majority of these reactions were non-serious, mild in intensity and resolved within 2 to 3 weeks.
Večina neželenih učinkov ni bila resnih, bili so blagi ter so izginili v roku 2 do 3 tednov.
The majority of these reactions were of mild to moderate severity and were not long lasting.
Večina teh učinkov je bila blagih do zmerno resnih in niso trajali dolgo.
The majority of these tumours occurred at the highest abacavir dose of 330 mg/kg/day in mice and 600 mg/kg/day in rats.
Večina teh tumorjev se je razvila pri dajanju najvišjih odmerkov, to je 330 mg/kg/dan pri miših in 600 mg/kg/dan pri podganah.
The majority of those patients exhibited transient low-titer ADA responses with no neutralising activity.
Večina teh bolnikov je imela prehoden odziv z nizkim titrom ADA in brez nevtralizirajoče aktivnosti.
The majority of treatment emergent adverse reactions were reported in <3% of subjects in any treatment group.
Pogostnost ve čine neželenih učinkov, povezanih z zdravljenjem, je bila <3% pri preskušancih v katerikoli terapevtski skupini.
The majority of treatment emergent adverse reactions were reported in <3% of subjects in any treatment group.
Pogostnost večine neželenih učinkov , povezanih z zdravljenjem, je bila <3% pri preskušancih v katerikoli terapevtski skupini.
The majority of women (74.6%) in the phase III studies had their next menstrual period at the expected time or within ± 7 days, while 6.8% experienced menses more than 7 days earlier than expected and 18.5% had a delay of more than 7 days beyond the anticipated onset of menses.
Večina žensk (74,6 %) je v študiji III. faze dobila naslednjo menstruacijo ob predvidenem času ali v obdobju ± 7 dni, 6,8% žensk je dobilo menstruacijo več kot 7 dni pred predvidenim datumom, pri 18,5 % pa je menstruacija zamujala več kot 7 dni po predvidenem datumu.
The maltol appeared to be rapidly metabolised to maltol glucuronide (Cmax = 4677 + 1613 ng/mL).
Videti je bilo, da se je maltol hitro presnovil v maltolov glukuronid (Cmax = 4677 + 1613 ng/ml).
The maltol appeared to be rapidly metabolised to maltol glucuronide (Cmax between 9.83 and 30.9 h.µg/mL across all dosage regimens).
Videti je bilo, da se je maltol hitro presnovil v maltolov glukuronid (Cmax med 9,83 in 30,9 h.µg/ml pri vseh režimih odmerjanja).
The management of adverse reactions may require treatment interruption, dose reduction, or treatment discontinuation (see Tables 1 and 2).
Obvladovanje neželenih učinkov lahko zahteva prekinitev zdravljenja, znižanje odmerka ali prenehanje zdravljenja (glejte preglednici 1 in 2).
The management of such patients should be directed by physicians with experience in the care of haemophilia A patients and those with factor VIII inhibitors.
Vodenje teh bolnikov mora voditi zdravnik z izkušnjami v zdravljenju bolnikov s hemofilijo A in tistih z inhibitorji faktorja VIII.
The management of such patients should be directed by physicians with experience in the care of patients with haemophilia and factor VIII inhibitors.
Obravnavo takih bolnikov mora voditi zdravnik z izkušnjami z zdravljenjem bolnikov s hemofilijo in zaviralci faktorja VIII.
The management plan for the patients who develop ONJ should be set up in close collaboration between the treating physician and a dentist or oral surgeon with expertise in ONJ.
Obravnava bolnikov, pri katerih se razvije osteonekroza čeljustnic, se mora načrtovati v tesnem sodelovanju med lečečim zdravnikom in zobozdravnikom ali čeljustnim kirurgom, ki ima izkušnje z osteonekrozo čeljustnic.
the manipulation, manufacture, storage, supply, distribution and sale of classical swine fever vaccines must be carried out under supervision and in accordance with the eventual instructions established by the competent authority of the Member State.
Izdelavo, skladiščenje, oskrbo, distribucijo in prodajo cepiv proti klasični prašičji kugi je treba izvajati pod nadzorstvom pristojnega organa v državi članici in v skladu z morebitnimi navodili, ki jih ta organ uvede.
The mannose acts as a substrate for the receptor, and the DTPA serves as a chelating agent for labelling with technetium Tc 99m.
Manoza deluje kot substrat za receptor, DTPA pa je kelator za označevanje s tehnecijem Tc99m.
The manual for patients with Gaucher Disease who receive home infusion should contain the following key elements:
Priročnik za bolnike z Gaucherjevo boleznijo, ki prejemajo infuzije na domu, mora vsebovati naslednje ključne elemente:
The manufacture, import, possession, sale supply and/or use of Ingelvac CircoFLEX may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.
Izdelava, uvoz, posedovanje, prodaja, oskrba in/ali uporaba cepiva CircoFLEX je lahko v državah članicah prepovedana na njihovem celotnem ozemlju ali delu ozemlja v skladu z nacionalnimi zakonodajami.
The manufacture, import, possession, sale, supply and/or use of AFTOVAXPUR DOE may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.
Proizvodnja, uvoz, posedovanje, prodaja, oskrba in/ali uporaba AFTOPURVAX DOE je lahko prepovedana v državah članicah na njihovem celotnem ozemlju ali delu ozemlja v skladu z nacionalno zakonodajo.
The manufacture, import, possession, sale, supply and/or use of BLUEVAC BTV8 may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.
Izdelava,uvoz/vnos, posedovanje, prodaja, oskrba in/ali uporaba BLUEVAC BTV8 je lahko v državi članici prepovedana na njenem celotnem ozemlju ali delu ozemlja v skladu z nacionalno zakonodajo.
The manufacture, import, possession, sale, supply and/or use of Bovela may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.
Izdelava, uvoz/vnos, posedovanje, prodaja, oskrba in/ali uporaba zdravila Bovela je lahko v državi članici prepovedana na njenem celotnem ozemlju ali delu ozemlja v skladu z nacionalno zakonodajo.
The manufacture, import, possession, sale, supply and/or use of Bovilis BTV8 is only allowed under the particular conditions established by European Community legislation on the control of bluetongue.
Izdelava, uvoz/vnos, posedovanje, prodaja, in/ali uporaba zdravila Bovilis BTV8 so dovoljeni le pod posebnimi pogoji, ki so določeni v zakonodaji Evropske skupnosti za nadzor nad boleznijo modrikastega jezika.
The manufacture, import, possession, sale, supply and/or use of Equilis West Nile may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.
Izdelava,uvoz, posedovanje, prodaja, oskrba in/ali uporaba zdravila Equilis West Nile je lahko v državi članici prepovedana na njenem celotnem ozemlju ali delu ozemlja v skladu z nacionalno zakonodajo.
The manufacture, import, possession, sale, supply and/or use of HIPRABOVIS IBR MARKER LIVE may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.
Izdelava,uvoz/vnos, posedovanje, prodaja, oskrba in/ali uporaba HIPRABOVIS IBR MARKER LIVE je lahko v državi članici prepovedana na njenem celotnem ozemlju ali delu ozemlja v skladu z nacionalno zakonodajo.
The manufacture, import, possession, sale, supply and/or use of Locatim may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.
Izdelava,uvoz/vnos, posedovanje, prodaja, oskrba in/ali uporaba Locatim je lahko v državi članici prepovedana na njenem celotnem ozemlju ali delu ozemlja v skladu z nacionalno zakonodajo.
The manufacture, import, possession, sale, supply and/or use of Nobilis IB 4-91 may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.
Izdelava, uvoz oziroma vnos, posedovanje, prodaja, oskrba in/ali uporaba zdravila Nobilis IB 4-91 je lahko v državi članici prepovedana na njenem celotnem ozemlju ali delu ozemlja v skladu z nacionalno zakonodajo.
The manufacture, import, possession, sale, supply and/or use of Parvoduk may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.
Izdelava,uvoz/vnos, posedovanje, prodaja, oskrba in/ali uporaba zdravilaje lahko v državi članici prepovedana na njenem celotnem ozemlju ali delu ozemlja v skladu z nacionalno zakonodajo.
The manufacture, import, possession, sale, supply and/or use of Suvaxyn Aujeszky 783 + O/W may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.
Izdelava,uvoz/vnos, posedovanje, prodaja, oskrba in/ali uporaba Suvaxyn Aujeszky 783 + O/W je lahko v državi članici prepovedana na njenem celotnem ozemlju ali delu ozemlja v skladu z nacionalno zakonodajo.
The manufacture, import, possession, sale, supply and/or use of Suvaxyn Circo+MH RTU may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.
Izdelava,uvoz/vnos, posedovanje, prodaja, oskrba in/ali uporaba Suvaxyn Circo+MH RTU je lahko v državi članici prepovedana na njenem celotnem ozemlju ali delu ozemlja v skladu z nacionalno zakonodajo.
The manufacture, import, possession, sale, supply and/or use of Suvaxyn CSF Marker vaccine may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.
Izdelava, uvoz/vnos, posedovanje, prodaja, oskrba in/ali uporaba zdravila Suvaxyn CSF Marker je lahko v državi članici prepovedana na njenem celotnem ozemlju ali delu ozemlja v skladu z nacionalno zakonodajo.
The manufacture, import, possession, sale, supply and/or use of Suvaxyn PCV may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.
Izdelava,uvoz/vnos, posedovanje, prodaja, oskrba in/ali uporaba Suvaxyn PCV je lahko v državi članici prepovedana na njenem celotnem ozemlju ali delu ozemlja v skladu z nacionalno zakonodajo.
The manufacture, import, possession, sale, supply and/or use of Vectormune ND may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.
Izdelava,uvoz/vnos, posedovanje, prodaja, oskrba in/ali uporaba Vectormune ND je lahko v državi članici prepovedana na njenem celotnem ozemlju ali delu ozemlja v skladu z nacionalno zakonodajo.
The manufacture, import, possession, sale, supply and/or use of Zulvac 1 Bovis may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.
Izdelava, uvoz/vnos, posedovanje, prodaja, oskrba in/ali uporaba Zulvac 1 Bovis je lahko v državi članici prepovedana na njenem celotnem ozemlju ali delu ozemlja v skladu z nacionalno zakonodajo.
The manufacture, import, possession, sale, supply and/or use of Zulvac 1 Ovis may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.
Izdelava, uvoz/vnos, posedovanje, prodaja, oskrba in/ali uporaba Zulvac 1 Ovis je lahko v državi članici prepovedana na njenem celotnem ozemlju ali delu ozemlja v skladu znacionalno zakonodajo.
The manufacture, import, possession, sale, supply and/or use of ZULVAC 1+8 Bovis may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.
Izdelava,uvoz/vnos, posedovanje, prodaja, oskrba in/ali uporaba ZULVAC 1+8 Bovis je lahko v državi članici prepovedana na njenem celotnem ozemlju ali delu ozemlja v skladu z nacionalno zakonodajo.
The manufacture, import, possession, sale, supply and/or use of ZULVAC 1+8 Ovis may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.
Izdelava,uvoz/vnos, posedovanje, prodaja, oskrba in/ali uporaba ZULVAC 1+8 Ovis je lahko v državi članici prepovedana na njenem celotnem ozemlju ali delu ozemlja v skladu z nacionalno zakonodajo.
The manufacture, import, sale, possession, supply and/or use of Zulvac 1 Bovis may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.
Izdelava, uvoz/vnos, posedovanje, prodaja, oskrba in/ali uporaba Zulvac 1 Bovis je lahko v državi članici prepovedana na njenem celotnem ozemlju ali delu ozemlja v skladu z nacionalno zakonodajo.
The manufacturer can be identified by the batch number printed on the slip of the carton and on the label:
Izdelovalca je mogoče ugotoviti po serijski številki, natisnjeni na škatli in nalepki:
The manufacturer is Shire Human Genetic Therapies AB, Åldermansgatan 2, P.O. Box 1117 SE-221 04 Lund, Sweden.
Izdelovalec je: Shire Human Genetic Therapies AB Åldermansgatan 2, P.O. Box 1117, SE-221 04 Lund, Švedska
The manufacturer is:
Izdelovalec je:
The manufacturer of Ketek is:
Izdelovalec zdravila Ketek je:
The manufacturer of VIAGRA is Fareva Amboise, Zone Industrielle, 29 route des Industries, 37530 Pocé-sur-Cisse, France.
Zdravilo VIAGRA izdeluje Fareva Amboise, Zone Industrielle, 29 route des Industries, 37530 Pocé- sur-Cisse, Francija.
The Manufacturer responsible for batch release is
Izdelovalec, odgovoren za sproščanje zdravila
The manufacturer's instructions for using the pen must be followed carefully for loading the cartridge, attaching the needle, and administering the insulin injection.
Navodila proizvajalca za uporabo peresnika morate natančno upoštevati, ko vstavljate vložek, pritrjujete iglo in dajete injekcijo insulina.
The manufacturer's instructions with each individual pen must be followed for loading the cartridge, attaching the needle and administering the insulin injection.
Pri vstavitvi vložka, pritrjevanju igle in dajanju injekcije insulina je treba upoštevati navodila izdelovalca, ki so priložena posameznim injekcijskim peresnikom.
The Manufacturer’s Instructions for Use of the Zirela Nebuliser System should be reviewed prior to the first use of Quinsair.
Pred prvo uporabo zdravila Quinsair je treba prebrati proizvajalčeva navodila za uporabo nebulatorskega sistema Zirela.
The Manufacturer’s Instructions for Use will give full details on cleaning and disinfecting.
V navodilih izdelovalca za uporabo najdete vse podrobnosti o čiščenju in razkuževanju.
The manufacturer’s instructions for using the pen must be followed carefully for loading the cartridge, attaching the injection needle, and administering the insulin injection.
Dosledno upoštevajte izdelovalčeva navodila za uporabo injekcijskega peresnika glede nameščanja vložka in injekcijske igle ter injiciranja insulina.
The manufacturer’s instructions for using the pen must be followed carefully for loading the cartridge, attaching the needle, and administering the insulin injection.
Dosledno spoštujte izdelovalčeva navodila za uporabo injekcijskega peresnika glede nameščanja vložka in igle ter injiciranja insulina.
The manufacturer’s instructions for using the pen must be followed carefully for loading the cartridge, attaching the needle, and administering the insulin injection.
Dosledno upoštevajte izdelovalčeva navodila za uporabo injekcijskega peresnika glede nameščanja vložka in igle ter injiciranja insulina.
The manufacturer’s instructions for using the pen must be followed carefully for loading the cartridge, attaching the needle, and administering the insulin injection.
Natančno je treba upoštevati izdelovalčeva navodila za uporabo injekcijskega peresnika, kar zadeva vstavljanje vložka, nameščanje igle in injiciranje insulina.
The manufacturer’s instructions for using the pen must be followed carefully for loading the cartridge, attaching the needle, and administering the insulin injection.
Navodila proizvajalca za uporabo peresnika morate natančno upoštevati, ko vstavljate vložek, pritrjujete iglo in dajete injekcijo insulina.
The manufacturer’s instructions with each individual pen must be followed for loading the cartridge, attaching the needle and administering the insulin injection.
Pri vstavitvi vložka, pritrjevanju igle in dajanju injekcije insulina je treba upoštevati navodila izdelovalca, ki so priložena posameznim injekcijskim peresnikom.
The manufacturer’s instructions with each individual transfer set and pen must be followed for reconstituting Omnitrope 5 mg/ml powder for solution for injection, loading the cartridge, attaching the injection needle and for the administration.
Izdelovalčeva navodila, ki so priložena vsakemu setu za prenos in injekcijskemu peresniku, je treba upoštevati pri pripravi zdravila Omnitrope 5 mg/ml prašek za raztopino za injiciranje, pri polnjenju vložka, pritrditvi injekcijske igle in pri uporabi.
The manufacturer’s instructions with each pen must be followed for loading the cartridge, attaching the injection needle and for the administration.
Izdelovalčeva navodila, ki so priložena injekcijskemu peresniku, je treba upoštevati pri polnjenju vložka, pritrditvi injekcijske igle in pri uporabi.
THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
IMETNIKA DOVOLJENJA ZA PROIZVODNJO ZDRAVILA, ODGOVORNEGA ZA SPROSTITEV SERIJ V EGP, ČE STA RAZLIČNA
THE MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE
IMETNIKI DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVORNI ZA SPROŠČANJE SERIJE
THE MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE‌
IMETNIKI DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVORNI ZA SPROŠČANJE SERIJE‌
The maraviroc dose should be
Pri sočasnem dajanju z okrepljenim
The maraviroc dose should be
Pri sočasnem dajanju z zdravilom
The maraviroc-resistant viruses remained CCR5-tropic and there was no conversion from a CCR5-tropic virus to a CXCR4- using virus.
Proti maraviroku odporni virusi so ostali CCR5-tropni in sprememba iz CCR5-tropnega virusa v virus uporabnik CXCR4 se ni pojavila.
the Marketing
študije za prihajajoče
The marketing authorisation for ECALTA is held by:
Imetnik dovoljenja za promet z zdravilom: